FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
60-Word AI Digest
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Key Takeaways
- FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
- The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
- Click full coverage link below for the complete official dispatch.
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Original Publisher Attribution
This summary was curated from CNBC.